Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy

REGENXBIO Inc. (NASDAQ:RGNX) is a biotech company developing AAV therapies for common and rare diseases. Its proprietary NAV platform creates one-dose AAV treatments that offer lasting therapeutic effects by targeting the root cause of diseases. AAV vectors deliver gene therapies to specific cells, maximizing efficacy and avoiding adverse immune responses. RGNX's pipeline includes promising candidates such as ABBV-RGX-314 for age-related AMD and DR, RGX-202 for DMD, and RGX-121 for Hunter syndrome. RGXN's s ...